Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 36th Annual J.P. Morgan Healthcare Conference 2018
8 slides from Jazz Pharmaceuticals's conference presentation, Jan 9, 2018
Slide 1: Relevant portion of transcript of Jazz presentation at J.P. Morgan conference
Exhibit 99.1 Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 8, 2018: Bruce Cozadd, Chairman & CEO, Jazz Pharmaceuticals plc … I will make forward-looking statements today. Of cou
Slide 2: Jazz Pharmaceuticals at 36th Annual J.P. Morgan Healthcare Conference
Relevant slides from Jazz Pharmaceuticals plc’s presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 8, 2018: 36th Annual Bruce January John, © 2018 Annual AML Cozadd Healthcare Jazz 8, 2018 patient J.P. Pharmaceuticals Chairman Morgan Conference and CEO all
Slide 3: Forward-Looking Statements and Safe Harbor
Forward-Looking “Safe This 2017 timing the uncertainties, introduction Administration commercializing (daunorubicin supply appropriate or opportunities future plc’s and to looking 2actual differ product timing inherently reports slide Securities financial Harbor” results, financial thereof; orstatem
Slide 4: Total Revenues
Strong TOTAL $2,000 September $1,800 212015 6guidance 2015 G=Guidance. 2016 Revenue Nine $1,6502 and REVENUES1 range 2017G 30 2016 months $1,600 provided Guidance $1,600 Growth audited; ended – $$1,488 in on Nine provided millions November $1,400 months by $1,325 Jazz ended 7, 2017. Pharmaceuticals
Slide 5: Xyrem Net Product Sales
NET $1,500 $1,180 2015 $0 $250 $500 Volume 16% expects year FDA-approved Disease Settlement Expect 102015 6% ended PRODUCT 2016 Nine – and low- (YOY) that, Growth awareness $12017G agreement December 2016 to months for ,2002 mid-single for < the audited; SALES1 1% efforts the $1,250 year ended with
Slide 6: Erwinaze Net Product Sales
NET $300 $250 $150 2015 1$0 expects financial Indicated Working 112015 PRODUCT Nine 2 $100 2016 $200 and that, with results asmonths $50 2017G 2016 afor –component product $215 for the audited; SALES1 ended the year $203 manufacturer year ended September Nine of $201 $ ended ainmulti-agent months mi
Slide 7: Defitelio Net Product Sales
NET $175 September $125 $150 2015 $0 $25 1$50 expects the Indicated EU U.S. Focused 122015 year Launch Launch PRODUCT Nine $109 2016 and that, ended medical for months $100 2017G 30 2016 2014 for 2016 the $130 December the $71 treatment audited; education SALES1 ended –year $75 $1502 ended Nine 31,
Slide 8: Vyxeos Net Product Sales
NET August 1$40 2017G $0 $10 $20 slightly Approved 13 EU Vyxeos Preparing G=Guidance. MAA - PRODUCT $30 11 granted above $30 submitted for in – September the potential the Guidance accelerated U.S. SALES1 guidance November inEU 30, August provided $approval 2017 assessment range in millions 2017 201
Jazz Pharmaceuticals — 36th Annual J.P. Morgan Healthcare Conference 2018 on 6ix